戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  a soluble extracellular domain of the human Nogo receptor.
2                                              Nogo receptor 1 (NGR1) activation of the GTPase RhoA is
3 nd that the plasticity inhibitors Nogo-A and Nogo receptor 1 (NgR1) are differentially expressed in t
4                          We examined whether Nogo Receptor 1 (NgR1) regulates the plasticity associat
5  white matter stroke is in part mediated via Nogo receptor 1 (NgR1) signaling.
6 -GFP, we reevaluated the CST in mice lacking nogo receptor 1 (NgR1), a protein implicated in limiting
7 ptors, only cellular prion protein (PrP(C)), Nogo receptor 1 (NgR1), and leukocyte immunoglobulin-lik
8 hibitors functioning as ligands for neuronal Nogo receptor 1 (NgR1).
9  in the somatosensory cortex of mice lacking Nogo Receptor 1 (NgR1).
10 ) to express a truncated soluble fragment of Nogo receptor 1 (NgSR).
11 axonal regeneration through interaction with Nogo receptor 1, but the function of Nogo-A in neurons i
12 -type and plasticity-sensitized mice lacking Nogo receptor 1.
13 ukocyte common antigen-related (LAR) and the nogo receptors 1 and 3 (NgR), have recently been identif
14 ors for myelin-associated growth inhibitors, Nogo receptors 1 and 3.
15  tyrosine phosphatase sigma (RPTPsigma), and Nogo receptors 1-3 (NgR1-3).
16  reported evidence that Nogo-A activation of Nogo-receptor 1 (NgR1) can drive axonal dystrophy during
17 lex with the neuronal cell surface receptors Nogo receptor-1 (NgR1) and paired Ig-like receptor-B (Pi
18 LOT usher substance (LOTUS) as an endogenous Nogo receptor-1 (NgR1) antagonist and demonstrated that
19 s) after contralateral pyramidotomy (PyX) in nogo receptor-1 knock-out mice and found that intact CSN
20  after pyramidotomy in plasticity sensitized nogo receptor-1-null mice.
21  functions including the gene coding for the Nogo receptor, a key transducer of myelin inhibition.
22                                              Nogo receptor adopts a leucine-rich repeat (LRR) module
23 mily of neuronal receptors that includes the NOGO receptor, an inhibitor of neuronal regeneration and
24  indicate that increased interaction between Nogo receptor and APP reduces surface expression of APP
25 tein found in CNS myelin, interacts with the Nogo receptor and has been proposed to mediate inhibitio
26  proteins including alcohol dehydrogenase-4, nogo receptor and interleukin-1 receptor antagonist prot
27 utgrowth inhibition by signaling through the Nogo receptor and paired Ig-like receptor B (PirB).
28  The NEP1-40 peptide competitively binds the Nogo receptor and partially blocks inhibition from MAIs,
29 motor area, inosine combined with NEP1-40, a Nogo receptor antagonist, doubled the number of axon bra
30 we examined the role of LOTUS, an endogenous Nogo receptor antagonist, in promoting functional recove
31 data are consistent with the hypotheses that Nogo receptors are membrane-bound growth cone repellent
32                                              Nogo receptors are sialoglycoproteins comprised of 8.5 c
33 l further with simultaneous application of a Nogo receptor blocking peptide, suggesting this combinat
34 ns and membrane-bound RTN4R proteins (a.k.a. NoGo receptors), but which of these ligands regulate spe
35 TN4-binding proteins were widely studied as "NoGo" receptors, but their physiological interactors and
36                   TROY is a component of the Nogo receptor complex and plays the key role in neuronal
37 hree inhibitors can interact with either the Nogo receptor complex or paired immunoglobulin-like rece
38                                          The Nogo receptor complex, composed of the Nogo-66 receptor
39 ons, LINGO-1 is an integral component of the Nogo receptor complex, which inhibits axonal growth via
40 ysis of p75(NTR), and ectodomain shedding of Nogo receptor, correlated with a 30% decrease in activat
41        This scientific commentary refers to 'Nogo receptor decoy promotes recovery and corticospinal
42 RhoGEF, binds p75 directly and regulates p75-Nogo receptor-dependent RhoA activation and neurite inhi
43 sitol-anchored cell-surface receptors of the Nogo Receptor family (NgR1, NgR2, and NgR3) restrict exc
44                           We demonstrate the Nogo receptor family (NgR1-3) acts as Abeta receptors me
45  interactions between MAG and members of the Nogo receptor family function to coordinate myelin inhib
46                                          The Nogo receptor family members NgR1 and NgR2 bind to MAIs
47                                      Soluble Nogo-Receptor-Fc decoy (AXER-204) blocks inhibitors of a
48                                  p75 and the Nogo receptor form a signaling unit for myelin inhibitor
49 ne-rich repeat and Ig-like domain-containing Nogo receptor interacting protein 1 (LINGO-1) is a negat
50 ne-rich repeat and Ig-like domain-containing Nogo receptor interacting protein 1 (LINGO-1) is a negat
51 e, we identify LRR and Ig domain-containing, Nogo receptor-interacting protein (LINGO-1) as a potent
52    Previously, LRR and Ig domain-containing, Nogo receptor-interacting protein (LINGO-1) has been ide
53  ligand-binding subunit of this complex, the Nogo receptor, is absent in oligodendrocytes, the extrac
54  acid or carrying a targeted deletion of the Nogo receptor (NgR(-/-)) unmasked a strong plasticity of
55 ned an expression library and identified the Nogo receptor (NgR) as a high-affinity OMgp-binding prot
56                                     Neuronal Nogo receptor (NgR) binds to each of the three inhibitor
57 family, is required as a co-receptor for the Nogo receptor (NgR) to mediate the activity of myelin-as
58 es suggest that an axon surface protein, the Nogo receptor (NgR), may play a role in this process thr
59                     When associated with the Nogo receptor (NgR), the transmembrane receptor p75NTR s
60                                              Nogo receptor (NgR)-mediated control of axon growth reli
61 to the glycosylphosphatidylinositol-anchored Nogo receptor (NgR).
62 xpression or suppressing the activity of the Nogo receptor (NgR).
63  (MAG), exert their effects through the same Nogo receptor (NgR).
64 izing the function of several members of the Nogo receptor (NgR)/RhoA pathway improved the capacity o
65           Three of these factors bind to the Nogo receptor, NgR, which is expressed on axons.
66           We demonstrate that reovirus binds Nogo receptor NgR1, a leucine-rich repeat protein expres
67 de of myelin-derived inhibitors with soluble Nogo receptor (NgR1, RTN4R) decoy protein.
68                                              Nogo receptors (NgR1, NgR2, and NgR3) are growth cone di
69 underway to investigate the effect of Nogo-A/Nogo-Receptor (NgR1) pathway blockers.
70                  We report that mice lacking Nogo receptors (NgR123-null mice) display complete CC ag
71 b) and glycosylphosphatidylinositol-anchored Nogo receptors (NgRs) as exclusive axonal receptors for
72 ce their inhibitory signals through the same Nogo receptor/p75 neurotrophin receptor/LINGO-1 (NgR1/p7
73 udy, we show that a family of proteins named Nogo receptor proteins (NgR1 to NgR3) regulates Abeta pr
74 site of APP mediates interaction of APP with Nogo receptor proteins.
75                    Thus, BAI binding to RTN4/NoGo receptors represents a receptor-ligand axis that, e
76                                Inhibition of Nogo receptors rescues NOM, but not to the extent exhibi
77 tion determines critical period onset, while Nogo receptor signaling is required for its closure.
78 eveloped a soluble, truncated version of the Nogo receptor that antagonizes outgrowth inhibition on b
79 entricular infusion of a soluble form of the Nogo receptor that blocks the action of several myelin-a
80 2 in neurons permits the accumulation of the Nogo receptor, thereby linking APC/C(Cdh1) activity with
81                                              Nogo receptor triple mutants (Ngr1(-/-); Ngr2(-/-); Ngr3
82 ue and axon regeneration is repressed by the Nogo receptor using p75NTR as the signal transducer.
83                                   A chimeric Nogo receptor variant (NgR(OMNI)) in which Cys(309)-Cys(
84 aves oligodendrocyte-myelin glycoprotein and Nogo receptors, was without benefit.
85 t residues (28-58) are available to bind the Nogo receptor, which is entirely consistent with functio